Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
“The final results of this study are further evidence that this new treatment approach, using a combination of three drugs, could provide people living with HR-positive, HER2-negative advanced breast cancer with an additional 10 months on average before their disease gets worse, giving them precious extra time with their loved ones.
“Final analysis of the results also showed that patients taking the three-drug combination including inavolisib on average had 7 more months to live compared to patients receiving standard treatment.
“This is a significant breakthrough and we’re proud that it builds on a series of discoveries that our funded scientists have been making at the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, since it opened 25 years ago.
“We now hope to see this new combination therapy can be licensed by the MHRA and assessed by NICE and the Scottish Medicine Council (SMC) as soon as possible so that it can reach the NHS patients who could benefit from it.
“Anyone affected by breast cancer can speak to Breast Cancer Now’s expert nurses by calling our free, confidential helpline on 0808 800 6000.”
ENDS